Adial Pharmaceuticals, Inc.
ADIL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001513525
In the last 90 days, Adial Pharmaceuticals, Inc. insiders filed 3 open-market purchases and 0 sales; 17 institutions reported holding it in 13F filings for Q2 2026, worth $334.6K in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Adial Pharmaceuticals, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +3 vs. Q3 2024
- Shares held
- 295.4K
- +99.2K (+50.6%) vs. Q3 2024
- Total value
- $298.1K
- +$102.1K (+52.1%) vs. Q3 2024
- New holders
- 4
- 3 more added
- Sold out
- 1
- 2 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADIL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $334.6K |
| Q1 2026 | 15 | $63.8K |
| Q4 2025 | 24 | $778.4K |
| Q3 2025 | 17 | $214.8K |
| Q2 2025 | 17 | $70.8K |
| Q1 2025 | 14 | $152.7K |
| Q4 2024 | 15 | $298.1K |
| Q3 2024 | 12 | $195.9K |
| Q2 2024 | 16 | $328.0K |
| Q1 2024 | 16 | $236.2K |
| Q4 2023 | 17 | $495.3K |
| Q3 2023 | 11 | $164.2K |
| Q2 2023 | 21 | $488.2K |
| Q1 2023 | 23 | $876.9K |
| Q4 2022 | 23 | $359.2K |
| Q3 2022 | 28 | $692.1K |
| Q2 2022 | 26 | $2.27M |
| Q1 2022 | 23 | $6.38M |
| Q4 2021 | 24 | $3.61M |
| Q3 2021 | 21 | $5.50M |
| Q2 2021 | 19 | $3.15M |
| Q1 2021 | 20 | $1.95M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Adial Pharmaceuticals, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 61,847 | $62.5K | 0.00% | +16,381+36.0% | Added |
| Citadel Advisors LLC | 54,508 | $55.1K | 0.00% | +21,238+63.8% | Added |
| Manchester Capital Management LLC | 48,097 | $48.6K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 47,613 | $48.1K | 0.00% | +47,613 | New |
| BlackRock, Inc. | 27,770 | $28.0K | 0.00% | 00.0% | Unchanged |
| Cambridge Investment Research Advisors, Inc. | 27,000 | $27.0K | 0.00% | +27,000 | New |
| UBS Group AG | 21,018 | $21.2K | 0.00% | +16,614+377.2% | Added |
| 1620 Investment Advisors, Inc. | 3,600 | $3.64K | 0.00% | 00.0% | Unchanged |
| Raffa Wealth Management, LLC | 2,093 | $2.11K | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 937 | $946 | 0.00% | +937 | New |
| Tower Research Capital LLC (TRC) | 638 | $644 | 0.00% | −3,305−83.8% | Reduced |
| Wells Fargo & Company | 160 | $162 | 0.00% | +160 | New |
| Bank of America Corp | 52 | $53 | 0.00% | 00.0% | Unchanged |
| Abound Wealth Management | 27 | $28 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 9 | $9 | 0.00% | −300−97.1% | Reduced |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −27,115−100.0% | Sold out |